4 Large Drug Stocks to Hold on to Amid Industry Challenges

After a rather weak 2023, the drug and biotech sector made a comeback initially in 2024 amid a slew of takeover deals. However, the sector has slowed down thereafter, mostly due to macroeconomic pressure.Concerns around the economy and inflation, regular pipeline setbacks and generic/biosimilar competition for blockbuster drugs are some headwinds of drug developers. Uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s (FTC) scrutiny of M&A deals in the sector r ...